Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
Info & Links
CEO
Abraham N. Ceesay
Headquarters
1325 BOYLSTON STREET,SUITE 401 BOSTON, MA 02215, UNITED STATES
Rapport Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
328.64M
Enterprise Value
289.22M
Enterprise Value/EBITDA(ttm)
-6.55
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
1.47
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
-10.81%
Return on Assets(ttm)
--
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-44.19M
Net Income Available to Common(ttm)
-58.33M
Diluted EPS(ttm)
--
Share Statistics
Beta (5Y Monthly)
--
52-Week Change
--
S&P 500 52-Week Change
7.67%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
36.58M
Dividend Yield
0.00%
Float4
0.00
% Held by Insiders
--
% Held by Institutions
--
Balance Sheet
Total Cash(mrq)
320.77M
Total Cash Per Share(mrq)
8.77
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
45.91%
Quick Ratio(mrq)
45.91%
Book Value Per Share(mrq)
8.83
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.45
Free Cash Flow(ytd)
-52.56M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.